Cargando…

Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer

PURPOSE: To report our experience with intensity-modulated or stereotactic reirradiation in patients suffering from recurrent nasopharyngeal carcinoma PATIENTS AND METHODS: The records of 17 patients with recurrent nasopharygeal carcinoma treated by intensity-modulated (n = 14) or stereotactic (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Roeder, Falk, Zwicker, Felix, Saleh-Ebrahimi, Ladan, Timke, Carmen, Thieke, Christian, Bischof, Marc, Debus, Juergen, Huber, Peter E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055828/
https://www.ncbi.nlm.nih.gov/pubmed/21356126
http://dx.doi.org/10.1186/1748-717X-6-22
_version_ 1782200145030414336
author Roeder, Falk
Zwicker, Felix
Saleh-Ebrahimi, Ladan
Timke, Carmen
Thieke, Christian
Bischof, Marc
Debus, Juergen
Huber, Peter E
author_facet Roeder, Falk
Zwicker, Felix
Saleh-Ebrahimi, Ladan
Timke, Carmen
Thieke, Christian
Bischof, Marc
Debus, Juergen
Huber, Peter E
author_sort Roeder, Falk
collection PubMed
description PURPOSE: To report our experience with intensity-modulated or stereotactic reirradiation in patients suffering from recurrent nasopharyngeal carcinoma PATIENTS AND METHODS: The records of 17 patients with recurrent nasopharygeal carcinoma treated by intensity-modulated (n = 14) or stereotactic (n = 3) reirradiation in our institution were reviewed. Median age was 53 years and most patients (n = 14) were male. The majority of tumors showed undifferentiated histology (n = 14) and infiltration of intracranial structures (n = 12). Simultaneous systemic therapy was applied in 8 patients. Initial treatment covered the gross tumor volume with a median dose of 66 Gy (50-72 Gy) and the cervical nodal regions with a median dose of 56 Gy (50-60 Gy). Reirradiation was confined to the local relapse region with a median dose of 50.4 Gy (36-64Gy), resulting in a median cumulative dose of 112 Gy (91-134 Gy). The median time interval between initial and subsequent treatment was 52 months (6-132). RESULTS: The median follow up for the entire cohort was 20 months and 31 months for survivors (10-84). Five patients (29%) developed isolated local recurrences and three patients (18%) suffered from isolated nodal recurrences. The actuarial 1- and 2-year rates of local/locoregional control were 76%/59% and 69%/52%, respectively. Six patients developed distant metastasis during the follow up period. The median actuarial overall survival for the entire cohort was 23 months, transferring into 1-, 2-, and 3-year overall survival rates of 82%, 44% and 37%. Univariate subset analyses showed significantly increased overall survival and local control for patients with less advanced rT stage, retreatment doses > 50 Gy, concurrent systemic treatment and complete response. Severe late toxicity (Grad III) attributable to reirradiation occurred in five patients (29%), particularly as hearing loss, alterations of taste/smell, cranial neuropathy, trismus and xerostomia. CONCLUSION: Reirradiation with intensity-modulated or stereotactic techniques in recurrent nasopharyngeal carcinoma is feasible and yields encouraging results in terms of local control and overall survival in patients with acceptable toxicity in patients with less advanced recurrences. However, the achievable outcome is limited in patients with involvement of intracranial structures, emphasising the need for close monitoring after primary therapy.
format Text
id pubmed-3055828
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30558282011-03-12 Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer Roeder, Falk Zwicker, Felix Saleh-Ebrahimi, Ladan Timke, Carmen Thieke, Christian Bischof, Marc Debus, Juergen Huber, Peter E Radiat Oncol Research PURPOSE: To report our experience with intensity-modulated or stereotactic reirradiation in patients suffering from recurrent nasopharyngeal carcinoma PATIENTS AND METHODS: The records of 17 patients with recurrent nasopharygeal carcinoma treated by intensity-modulated (n = 14) or stereotactic (n = 3) reirradiation in our institution were reviewed. Median age was 53 years and most patients (n = 14) were male. The majority of tumors showed undifferentiated histology (n = 14) and infiltration of intracranial structures (n = 12). Simultaneous systemic therapy was applied in 8 patients. Initial treatment covered the gross tumor volume with a median dose of 66 Gy (50-72 Gy) and the cervical nodal regions with a median dose of 56 Gy (50-60 Gy). Reirradiation was confined to the local relapse region with a median dose of 50.4 Gy (36-64Gy), resulting in a median cumulative dose of 112 Gy (91-134 Gy). The median time interval between initial and subsequent treatment was 52 months (6-132). RESULTS: The median follow up for the entire cohort was 20 months and 31 months for survivors (10-84). Five patients (29%) developed isolated local recurrences and three patients (18%) suffered from isolated nodal recurrences. The actuarial 1- and 2-year rates of local/locoregional control were 76%/59% and 69%/52%, respectively. Six patients developed distant metastasis during the follow up period. The median actuarial overall survival for the entire cohort was 23 months, transferring into 1-, 2-, and 3-year overall survival rates of 82%, 44% and 37%. Univariate subset analyses showed significantly increased overall survival and local control for patients with less advanced rT stage, retreatment doses > 50 Gy, concurrent systemic treatment and complete response. Severe late toxicity (Grad III) attributable to reirradiation occurred in five patients (29%), particularly as hearing loss, alterations of taste/smell, cranial neuropathy, trismus and xerostomia. CONCLUSION: Reirradiation with intensity-modulated or stereotactic techniques in recurrent nasopharyngeal carcinoma is feasible and yields encouraging results in terms of local control and overall survival in patients with acceptable toxicity in patients with less advanced recurrences. However, the achievable outcome is limited in patients with involvement of intracranial structures, emphasising the need for close monitoring after primary therapy. BioMed Central 2011-03-01 /pmc/articles/PMC3055828/ /pubmed/21356126 http://dx.doi.org/10.1186/1748-717X-6-22 Text en Copyright ©2011 Roeder et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Roeder, Falk
Zwicker, Felix
Saleh-Ebrahimi, Ladan
Timke, Carmen
Thieke, Christian
Bischof, Marc
Debus, Juergen
Huber, Peter E
Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
title Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
title_full Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
title_fullStr Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
title_full_unstemmed Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
title_short Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
title_sort intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055828/
https://www.ncbi.nlm.nih.gov/pubmed/21356126
http://dx.doi.org/10.1186/1748-717X-6-22
work_keys_str_mv AT roederfalk intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT zwickerfelix intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT salehebrahimiladan intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT timkecarmen intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT thiekechristian intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT bischofmarc intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT debusjuergen intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer
AT huberpetere intensitymodulatedorfractionatedstereotacticreirradiationinpatientswithrecurrentnasopharyngealcancer